Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.
Introducing Boostrix
Boostrix is indicated for booster vaccination against diphtheria, tetanus and pertussis of individuals from the age of 4 years
onwards. 1
References:
- Boostrix Patient Information Leaflet. Available at https://old.sfda.gov.sa/ar/SURE_DrugList_Attachments/694-human-EnPamphlet-1.3.3.2%20English%20Leaflet.pdf
- Tran Minh N, He Q, Ramalho A, et al. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics 1999;104:1–6.
- Knuf M, Zepp F, Meyer C, et al. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population. Vaccine 2006;24:2043–2048.
- Turnbull FM, Heath TC, Jalaludin BB, et al. A randomized trial of 2 acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults. Vaccine 2001;19:628–636.
- Van Damme P, Burgess M. Immunogenicity of a combined diphtheria-tetanus-acellular pertussis vaccine in adults. Vaccines 2004;22:305–308.
- Chan SH, Tan PT, Han HH, et al. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults. Singapore Med J 2006;47:286–290.
- Kosuwon P, Warachit B, Hutagalung Y, et al. Reactogenicity and immunogenicity of reduced antigen content diphtheria–tetanus–acellular pertussis vaccine (dTpa) administered as a booster to 4–6 year-old children primed with 4 doses of whole-cell pertussis vaccine. Vaccine 2003;21:4194–4200.
Boostrix is a registered trademark of the GSK group of companies
